austin said recent population-level studies have shown that coffee and tea drinkers have a reduced risk of death from cardiovascular disease, but a biochemical explanation of this phenomenon has previously eluded researchers.
“these findings have wide ranging implications as they connect this widely consumed, biologically active compound to cholesterol metabolism at a molecular level,” said study co-author guillaume paré, professor in mcmaster’s department of pathology and molecular medicine.
“this discovery was completely unexpected and shows that ordinary food and drink have many more complex effects than we think.”
together with co-author and medicinal chemist jakob magolan, the team has developed new caffeine derivatives that potently lower blood pcsk9 levels, potentially leading to new ldl cholesterol treatments.
“we are excited to be pursuing this new class of medicines – or nutraceuticals – for the potential treatment and prevention of cardiovascular disease,” said magolan, associate professor in the department of biochemistry and biomedical sciences at mcmaster.
researchers are also exploring additional health benefits of caffeine and its derivatives beyond those observed in the present study.
“it is exciting to see yet another potential clinical benefit from caffeine,” said mark tarnopolsky, division head of neuromuscular and neurometabolic disorders at mcmaster’s department of pediatrics.
the study was co-led by austin and lebeau, from the hamilton centre for kidney research at the research institute of st. joe’s hamilton.
austin and lebeau’s team included researchers from several mcmaster university departments, as well as the libin cardiovascular institute of alberta at the university of calgary and the clinical research institute of montreal, affiliated with the university of montreal.